Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G. velutinum n-butanol fraction is a phytochemical extract derived from the leaves of the plant *Glochidion velutinum*. It is prepared by fractionating a crude methanolic extract using n-butanol to isolate a specific profile of secondary metabolites, including phenolic compounds and flavonoids. In preclinical research, this fraction has been evaluated for its cytotoxic activity against prostate cancer (PC-3) and breast cancer (MCF-7) cell lines. The extract's bioactivity is attributed to a complex mixture of phytochemicals such as epigallocatechin gallate (EGCG), ellagic acid, isovitexin, and rutin, which are known to possess antineoplastic properties. Studies indicate that the fraction exhibits selective toxicity toward cancer cells with negligible effects on normal macrophages, suggesting potential for further development as a therapeutic lead in oncology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glochidion velutinum n-butanol fraction.